No Data
No Data
Kintor Pharmaceutical Chairman/CEO Boosts Shareholding
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Tong Youzhi, the Chairman of the Board of Directors and Executive Director cum CEO of Kai Tak Pharmaceutical (09939.HK), increased his shareholding by 0.9955 million shares.
Kaituo Pharmaceutical-B (09939.HK) announced that Tong Youzhi (Chairman of the Board of Directors, Executive Director and CEO of the Company) has increased his shareholding by a total of 1.0265 million Hong Kong dollars (an average fill price of 1.0311 Hong Kong dollars per share) through his wholly-owned company KT International Investment Limited on the public market on July 19, 24 and 25, 2024, which increased a total of 0.9955 million shares of the Company, accounting for about 0.22% of the Company's total issued share capital as of the date of this announcement.
Express News | Kintor Pharmaceutical - CEO via KT International Investment Bought 995,500 Shares of Co in Open Market for Aggregate of HK$1.0 Mln From July 19-25
SmartHK shareholder equity disclosure | July 22nd
HK shareholders' equity disclosure | July 22nd
No Data